Posttranslational modifications in cancer
Recent publications
Nasr R, Guillemen MC, Ferhi O, Soilihi H, Peres L, Berthier C, Lallemand-Breitenbach V, Zhu J, de Thé H. APL leukemia initiating cell eradication through cooperative cAMP- RA- and arsenic-triggered PML/RARA degradation. Nature Medecine 2008 Dec;14(12):1333-42.
Zhu, R. Nasr, L. Peres, F. Riaucoux, N. Honoré, C. Berthier, D. Kamashev, J. Zhou, D. Vitoux, C. Lavau, H. de Thé (2007) RXR is an essential component of the oncogenic PML/RARA complex in vivo Cancer Cell 12, 23,35
Lallemand, V. de Thé, H. (2006) CK2 and PML:regulating the regulator. Cell 126:244-5
Zhou, J., Peres, L., Honoré, N., Nasr, R., Zhu, J., de Thé, H. (2006) Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. PNAS 103:9238-43
Zhu, J., Zhou, J., Peres, L. , Riaucoux, F., Honoré, N., Kogan, S. H. de Thé (2005) A sumolation site is essential for PML/RARA transformation Cancer Cell 7: 143-154.
Lallemand-Breitenbach V, Zhu J, Kogan S, Chen Z, de Thé H. (2005) How patients have benefited from mouse APL models. Nature Reviews Cancer. 5:821-7.
Kamashev, D. Vitoux, D., de Thé H (2004) PML/RARA-RXR oligomers mediate retinoid- and rexinoid- /cAMP cross-talks in APL cell differentiation J. Exp. Med. 199, 1-13.
